Barclays Starts SAB Biotherapeutics (SABS) at Overweight

June 24, 2026 6:20 AM EDT Send to a Friend
(Updated - June 24, 2026 6:20 AM EDT)

Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ: SABS) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login